Clinical Trial Update: Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC [Phase 2]

View source ↗

Summary

Phase 2 trial of Vebrekotuzumab with or without an anti-PD-1 antibody for pretreatment advanced esophageal squamous cell carcinoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Anti-PD-1 antibody
• Vebrekotuzumab (Vebrekotuzumab)

Snippet

Sponsor: Fudan University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: SUSPENDED